Efficacy differences of acute-phase strategies for adult depression: A comprehensive network meta-analysis based on evidence from 2019 to 2024
Journal of Affective Disorders · 2026-07 · 405 · 121545
DOI: 10.1016/j.jad.2026.121545 ↗Kurz gefasst
Netzwerk-Metaanalyse in der Zeitschrift Journal of Affective Disorders, 2026-07. Verfasst von Jun-Zhe Ci und 4 weiteren Autor:innen. Beteiligte Einrichtung: College of Health, Fujian Medical University, 350122, Fuzhou, Fujian, China. Hauptthemen laut MEDLINE: Antidepressive Agents, Depression, Depressive Disorder, Psychotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: Fujian Medical University.
Themen: Depression
Abstract (Originalsprache)
Depression, a condition severely endangering individual health and societal progress, is projected by the WHO to become the leading global disease burden by 2030. Currently, three categories of therapies are employed in clinical practice: psychotherapy, pharmacotherapy, and physical therapy. The treatment strategies utilized include monotherapy with each of the three modalities and combination therapy involving any two of them. However, the clinical efficacy of these treatment strategies remains unclear. Through a network meta-analysis, this study evaluated and compared the therapeutic effects of monotherapies and various combination therapies over the past five years. This study included 67 articles published between 2019 and 2024, totaling 7351 patients. The results demonstrated that, in the efficacy comparison of monotherapies, the three treatment modalities showed no significant differences in treatment response and remission rates during the acute phase of adult depression. In the efficacy comparison between combination therapies and monotherapies, we found that the combination of psychotherapy and pharmacotherapy significantly outperformed both corresponding monotherapies. Specifically, we found that the response rate for SSRIs/BZDs combined with CBT was significantly higher than that for CBT monotherapy or SSRIs/BZDs monotherapy. Through effect-size analysis, we further observed that this advantage is not merely an additive effect of the two treatment modalities, but rather a synergistic enhancement arising from their mutual synergy, which amplifies their respective therapeutic efficacy. Furthermore, we found no evidence that combining psychotherapy or pharmacotherapy with physical therapy conferred any significant advantage over monotherapy. This study provides supporting evidence and references for the clinical practice of combination therapy strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Health, Fujian Medical University, 350122, Fuzhou, Fujian, China.
- Xiamen University Tan Kah Kee College, 353000, Zhangzhou, Fujian, China. Electronic address: spencer@xujc.com.
- College of Health, Fujian Medical University, 350122, Fuzhou, Fujian, China. Electronic address: Lihualin7778@fjmu.edu.cn.
Förderung
- Fujian Medical University
Zitieren
APA
Ci, J. Z., Guo, Z. B., Lin, N. Y., Zhang, H. Z., & Lin, L. H. (2026). Efficacy differences of acute-phase strategies for adult depression: A comprehensive network meta-analysis based on evidence from 2019 to 2024. Journal of Affective Disorders, 405, 121545. https://doi.org/10.1016/j.jad.2026.121545
Vancouver
Ci JZ, Guo ZB, Lin NY, Zhang HZ, Lin LH. Efficacy differences of acute-phase strategies for adult depression: A comprehensive network meta-analysis based on evidence from 2019 to 2024. Journal of Affective Disorders. 2026;405:121545. doi:10.1016/j.jad.2026.121545
BibTeX
@article{Ci2026,
author = {Ci, Jun-Zhe and Guo, Zhi-Bin and Lin, Nan-Yu and Zhang, Hui-Zhen and Lin, Li-Hua},
title = {Efficacy differences of acute-phase strategies for adult depression: A comprehensive network meta-analysis based on evidence from 2019 to 2024},
journal = {Journal of Affective Disorders},
year = {2026},
volume = {405},
pages = {121545},
doi = {10.1016/j.jad.2026.121545}
}
EUVIMED